Article info

Download PDFPDF

Hydroxychloroquine dosing in systemic lupus erythematosus: response to ‘Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al’ by Costedoat-Chalumeau et al

Authors

  • Antonis Fanouriakis Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece PubMed articlesGoogle scholar articles
  • George Bertsias Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Dimitrios T Boumpas Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Dimitrios T Boumpas, Medicine, National and Kapodestrian University of Athens, 12462 Athens, Greece; boumpasd{at}uoc.gr
View Full Text

Citation

Fanouriakis A, Bertsias G, Boumpas DT
Hydroxychloroquine dosing in systemic lupus erythematosus: response to ‘Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al’ by Costedoat-Chalumeau et al

Publication history

  • Received May 5, 2019
  • Accepted May 6, 2019
  • First published June 14, 2019.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.